C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s

AIDS

Volumn 18, Issue 18, 2004, Pages 2434-2437

  Henry, Keith ^a   Kitch, Douglas ^b   Dube, Michael ^c   Zackin, Robert ^b   Parker, Robert A ^b   Sprecher, Dennis ^d   Hammer, Scott ^e   Currier, Judith ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c INDIANA UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INDINAVIR;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; RISK FACTORS;

EID: 11244341468     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. The HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
3. Walli R, Herfort O, Michl CM, Demant T, Jager H, Dieterle C, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 1998; 12:F167-F173.
4. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, Daly J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
5. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-710.
6. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
7. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
8. Zietz C, Hotz B, Sturzl M, Rauch E, Penning R, Lohrs U. Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. Am J Pathol 1996; 149:1887-1898.
9. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143.
11. Ridker P, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein level and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843.
13. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
14. Danesh J, Wheeler GJ, Hirshfield GM, Eda S, Eiriksdottir C, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
15. Tall AR. C-reactive protein reassessed. N Engl J Med 2004; 305:1450-1452.
16. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in human immunodeficiency virus infected persons with CD4+ T-lymphocyte counts less than or equal to 200 per cubic millimeter. N Engl J Med 1997; 337:725-733.
17. Hammer S, Bassett R, Fischl M, Squires K, Demeter L, Currier J, et al. Randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with plasma HIV RNA < 500 copies/ml. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 8-11 February 2004 [Abstract 56].
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
19. Wilson PFW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
20. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and American College of Cardiology. Circulation 1999; 100:1481-1492.
21. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124:654-663.
22. Treitinger A, Spada C, da Salva LM, Hermes EM, Amaral JA, Abdalla DSP. Lipid and acute-phase protein alterations inHIV-1 infected patients in the early stages of infection. Brazil J Infect Dis 2001; 5:192-199.
23. Jahoor F, Gazzard B, Phillips G, Sharpstone D, Delrosario M, Frazer ME, et al. The acute-phase protein response to human immunodeficiency virus infection in human subjects. Am J Physiol 1999; 276:E1092-E1098.
24. Storgaard M, Laursen AL, Anderson PL. The C-reactive protein response in HIV-infected patients with pneumonia. Scand J Infect Dis 1993; 25:305-309.
25. Grutzmeier S, Sandstrom E. C-reactive protein levels in HIV complicated by opportunistic infections and infections with common bacterial pathogens. Scand J Infect Dis 1999; 31:229-234.
26. Melchior JC, Niyongabo T, Henzel D, Durack Sown I, Henri SC, Boulier A. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition 1999; 15:865-869.
27. Feldman JG, Goldwasser P, Holman S, DeHovitz, Minkoff H. C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr 2003; 32:210-214.
28. Meng Q, Lima JAC, Lai H, Vlahov D, Celentano DD, Strathdee SA, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002; 144:642-648.
29. Sklar P, Blackwelder W, Csako G, Metcalf J, Dybul M, Polis M, et al. C-reactive protein may be an important biomarker of cardiovascular risk and does not appear to be confounded by antiretroviral use or HIV viremia. In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts, 10-14 February 2003 [Abstract 742].
30. Mooser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 2003; 17 (Suppl. 1):S65-S69.
31. Sklar P, Masur P. HIV infection and cardiovascular disease - is there really a link? N Engl J Med 2003; 349:2065-2067.
32. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance due to HIV protease inhibitors. AIDS 1998; 12:F51-F58.
33. Dube MP, Edmondson-Melancon H, Qian D, Aqeel R, Johnson DJ, Buchanan TA. Prospective evaluation of effect of initiating indinavir-based therapy on insulin sensitivity and β-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 27:130-134.
34. Noor MA, Lo JC, Mulligan K, Schwartz JM, Halvorsen RA, Schamgelan M, Grunfeld C. Metabolic effects of indinavir in healthy HIV-negative men. AIDS 2001; 15:F11-F18.